HbA1c Testing Devices Market To Reach $3.15 Billion By 2030

HbA1c Testing Devices Market Growth & Trends

The global HbA1c testing devices market size is anticipated to reach USD 3.15 billion by 2030, growing at a CAGR of 6.48% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for HbA1c testing devices is witnessing significant growth, driven by the rising prevalence of diabetes and the demand for accurate and efficient monitoring solutions. According to the CDC, in 2021, 38.4 million  Americans, or 11.6% of the population, had diabetes. This includes 2 million Americans with type 1 diabetes, approximately 304,000 of whom are children and adolescents. The report also highlights that 1.2 million Americans are diagnosed with diabetes annually, underscoring the persistent need for diabetes care and management. HbA1c testing plays a crucial role in diabetes management by providing valuable insights into long-term blood sugar control and assisting healthcare providers in optimizing patient treatment plans.

The importance of glycemic control and HbA1c testing devices drive market growth by increasing demand for accurate monitoring tools, fostering innovation, and expanding market reach, particularly in low- and middle-income countries. Inadequate control leads to complications, impacting patients' quality of life and healthcare costs. According to a study, the Diabetes Control and Complications Trial (DCCT) shows that strict glucose control reduces long-term complications, highlighting the cost-effectiveness of intensive treatment. In low- and middle-income countries (LMICs), owing to late diagnosis, glycemic control and patient education become crucial. This, in turn, propels the need for early diagnosis, systematic complication screening, and timely treatment intensification to lower costs compared to inpatient care and treatment of complications.

The market is witnessing a notable shift towards Point-of-care (POC) testing devices, which offer rapid results, enabling timely interventions and personalized treatment plans. POC devices are gaining extensive popularity in homecare settings, enabling patients to monitor their HbA1c levels conveniently and effectively. This trend reflects the growing emphasis on patient-centric care and adoption of remote monitoring solutions in healthcare.

Key market players such as ARKRAY, Inc., Abbott Laboratories, Chek, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc., Trivitron Healthcare, EKF Diagnostics, and Tosoh Corporation are at the forefront of innovation in HbA1c testing devices. These companies are constantly focusing on developing advanced technologies to enhance the accuracy, speed, and user-friendliness of HbA1c testing devices, catering to the evolving needs of healthcare professionals and patients. For instance, in August 2022 , DxGen Corp. and Precision Diabetes, Inc. partnered to launch Epithod AutoDx, an automatic point-of-care analyzer for diabetes tests, including HbA1c. With a user-friendly design, it enables rapid results in settings such as physician offices and clinics, addressing the growing demand for on-site testing amid the pandemic.

 Request a free sample copy or view report summary: HbA1c Testing Devices Market Report

HbA1c Testing Devices Market Report Highlights

• Point-of-care (POC) testing devices dominated the HbA1c type of device segment and are anticipated to grow at the fastest CAGR over the forecast period owing to their vital use for informed decision-making in diabetes management.

• Immunoassays dominated the technology segment attributed to rapid and simplified results associated with the technology.

• The hospitals and clinics end-use segment dominated the market in 2023, which is attributed to the well-equipped advanced technology and infrastructure available in hospitals and clinics to handle these devices effectively.

• North America dominated the HbA1c testing devices industry owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment.

HbA1c Testing Devices Market Segmentation

Grand View Research has segmented the global HbA1c testing devices market based on type of device, technology, end-use, and region:

HbA1c Testing Devices Type of Device Outlook (Revenue, USD Million, 2018 - 2030)

• Laboratory-based Testing Devices

• Point-of-care (POC) Testing Devices

HbA1c Testing Devices Technology Outlook (Revenue, USD Million, 2018 – 2030)

• Immunoassays

• Chromatography

• Enzymatic Assays

• Boronate Affinity Chromatography

• High-Performance Liquid Chromatography

• Others

HbA1c Testing Devices End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostic Laboratories

• Homecare Settings

HbA1c Testing Devices Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in HbA1c Testing Devices Market

• Bio-Rad Laboratories, Inc.

• Abbott

• F. Hoffmann-La Roche Ltd  

• Siemens Healthineers AG

• HUMAN

• Trinity Biotech

• Menarini Diagnostics s.r.l

• SAKAE CO. LTD.

• Ceragem Medisys Inc

• SEKISUI MEDICAL CO., LTD.